Genetic variation in myeloperoxidase modifies the association of serum α-tocopherol with aggressive prostate cancer among current smokers.

We investigated associations of serum α- and γ-tocopherols and their effect modification by polymorphisms in oxidative stress regulatory enzymes in relation to prostate cancer risk. In a nested case-control study in the Carotene and Retinol Efficacy Trial, prerandomized serum α- and γ-tocopherol were assayed among 684 men with incident prostate cancer [375 nonaggressive and 284 aggressive cancer (stage III/IV or Gleason score ≥7)] and 1441 controls. Manganese superoxide dismutase Ala-16Val (rs4880), glutathione peroxidase 1 Pro200Leu (rs1050450), catalase -262 C > T (rs1001179), and myeloperoxidase (MPO) G-463A (rs2333227) were genotyped. A multivariate-adjusted inverse association of serum α-tocopherol with total prostate cancer risk was observed in current smokers (OR = 0.62, 95% CI = 0.40-0.96, 4th vs. 1st quartiles). High (≥median) compared to low serum concentrations of α- and γ-tocopherol were inversely associated with aggressive prostate cancer in current smokers (OR = 0.50, 95% CI = 0.32-0.78 and OR = 0.64, 95% CI = 0.43-0.95, respectively). The association was stronger among those with MPO G/A+A/A genotypes. Among current smokers with low serum α-tocopherol concentrations, MPO G/A+A/A, the genotypes downregulating oxidative stress, were associated with an increased risk for aggressive prostate cancer (OR = 2.06, 95% CI = 1.22-3.46). Conversely, current smokers with these genotypes who had high α-tocopherol concentrations had a reduced risk for aggressive prostate cancer (OR = 0.34, 95% CI = 0.15-0.80; P-interaction = 0.001). In conclusion, among current smokers, both high serum α- and γ-tocopherol concentrations were associated with reduced risks of aggressive prostate cancer. The α-tocopherol-associated risks are modified by polymorphism in MPO G-463A.

[1]  A. Kong,et al.  Cancer-preventive activities of tocopherols and tocotrienols. , 2010, Carcinogenesis.

[2]  S. Koul,et al.  Oxidative stress in prostate cancer. , 2009, Cancer letters.

[3]  M. Thun,et al.  Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk. , 2009, Carcinogenesis.

[4]  Brice A P Wilson,et al.  Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer , 2009, Proceedings of the National Academy of Sciences.

[5]  P. Gann.  Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance--next, cause. , 2009, JAMA.

[6]  J. Manson,et al.  Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. , 2009, JAMA.

[7]  J. Crowley,et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.

[8]  D. Hunter,et al.  A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk , 2009, Breast Cancer Research and Treatment.

[9]  T. Perfetti,et al.  The Chemical Components of Tobacco and Tobacco Smoke , 2008 .

[10]  H. Grönberg,et al.  Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. , 2008, Cancer research.

[11]  D. Spiegelman,et al.  Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. , 2008, Carcinogenesis.

[12]  A. Kristal,et al.  Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. , 2008, Carcinogenesis.

[13]  Emily White,et al.  Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort , 2008, Cancer Causes & Control.

[14]  F. Berrino,et al.  Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. , 2007, The American journal of clinical nutrition.

[15]  R. Hayes,et al.  Functional Variant of Manganese Superoxide Dismutase (SOD2 V16A) Polymorphism Is Associated with Prostate Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[16]  A. Kristal,et al.  Polymorphisms in Oxidative Stress–Related Genes Are Not Associated with Prostate Cancer Risk in Heavy Smokers , 2007, Cancer Epidemiology Biomarkers & Prevention.

[17]  C. Ambrosone,et al.  Associations between Catalase Phenotype and Genotype: Modification by Epidemiologic Factors , 2006, Cancer Epidemiology Biomarkers & Prevention.

[18]  U. Vogel,et al.  Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. , 2006, Carcinogenesis.

[19]  A. Neugut,et al.  Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. , 2005, American journal of epidemiology.

[20]  P. Kantoff,et al.  Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. , 2005, Cancer research.

[21]  D. Albanes,et al.  Serum α-Tocopherol and γ-Tocopherol in Relation to Prostate Cancer Risk in a Prospective Study , 2005 .

[22]  Keshav K. Singh,et al.  Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. , 2005, Cancer research.

[23]  D. Albanes,et al.  Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. , 2005, Journal of the National Cancer Institute.

[24]  A. Neugut,et al.  Myeloperoxidase Genotype, Fruit and Vegetable Consumption, and Breast Cancer Risk , 2004, Cancer Research.

[25]  M. Evans,et al.  Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145. , 2004, Carcinogenesis.

[26]  D. Albanes,et al.  Manganese superoxide dismutase (MnSOD) polymorphism, α-tocopherol supplementation and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (Finland) , 2003, Cancer Causes & Control.

[27]  A. Diamond,et al.  Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. , 2003, Cancer research.

[28]  G. Omenn,et al.  Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  D. Pessayre,et al.  The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. , 2003, Pharmacogenetics.

[30]  M. Moyad,et al.  Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? , 2002, Urology.

[31]  増田 光治.  Chlorination of guanosine and other nucleosides by hypochlorous acid and myeloperoxidase of activated human neutrophils : Catalysis by nicotine and trimethylamine , 2002 .

[32]  U. de Faire,et al.  Oxidative stress, human genetic variation, and disease. , 2001, Archives of biochemistry and biophysics.

[33]  E. Giovannucci.  Gamma-tocopherol: a new player in prostate cancer prevention? , 2000, Journal of the National Cancer Institute.

[34]  J. S. Morris,et al.  Association Between α-Tocopherol, γ-Tocopherol, Selenium, and Subsequent Prostate Cancer , 2000 .

[35]  D. Albanes,et al.  Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. , 2000, Cancer research.

[36]  J. S. Morris,et al.  Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. , 2000, Journal of the National Cancer Institute.

[37]  E. Rimm,et al.  Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  W. Willett,et al.  Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. , 1999, Cancer research.

[39]  W. Willett.  Biochemical Indicators of Dietary Intake , 1998 .

[40]  S. Ripatti,et al.  Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. , 1998, Journal of the National Cancer Institute.

[41]  M. Katan.  Biochemical indicators of dietary intake. , 1998 .

[42]  L. Oberley,et al.  Expression of antioxidant enzymes in human prostatic adenocarcinoma , 1997, The Prostate.

[43]  G. Stemmermann,et al.  Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[44]  H. Sies,et al.  Oxidative stress: oxidants and antioxidants , 1997, Experimental physiology.

[45]  Gordon Vansant,et al.  An Alu Element in the Myeloperoxidase Promoter Contains a Composite SP1-Thyroid Hormone-Retinoic Acid Response Element* , 1996, The Journal of Biological Chemistry.

[46]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[47]  M. Eichholzer,et al.  Prediction of male cancer mortality by plasma levels of interacting vitamins: 17‐year follow‐up of the prospective Basel study , 1996, International journal of cancer.

[48]  J. Morrow,et al.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. , 1995, The New England journal of medicine.

[49]  M. Meydani.  Vitamin E , 1995, The Lancet.

[50]  R. Peto,et al.  Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. , 1988, American journal of epidemiology.